HLA-DQA2 DQB2 Modulation for Asthma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately identify causal variants and genes contributing to asthma risk within the highly complex and polymorphic human leukocyte antigen (HLA) region, making it challenging to determine disease-associated variants and their functions.
Innovation Solution
The development of methods to modulate the activity and expression of HLA-DQA2 and HLA-DQB2, including the use of inhibitors and gene editing techniques to target specific SNPs, for the treatment and prevention of asthma, as well as the characterization of asthma risk through biomarker analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If GWAS studies focus on associations with individual SNPs in the HLA region, then statistical associations with asthma risk can be identified, but the complexity of allelic variation and linkage disequilibrium prevents accurate identification of causal variants and genes
Solution Approach 1:
The patent segments the HLA region analysis by focusing on specific functional elements (peptide binding groove, alpha helices, beta sheets) rather than treating the entire region as a monolithic complex. This allows systematic evaluation of specific structural features that may drive asthma susceptibility while managing the overall complexity through targeted analysis.
Solution Approach 2:
The patent changes the analytical parameters from individual SNP associations to structural and functional characteristics of HLA molecules. By evaluating parameters such as peptide binding affinity, molecular structure, and functional activity, the study transitions from statistical correlation to mechanistic understanding, thereby identifying causal variants more accurately despite the region's complexity.
2Loss of information
If the HLA region is analyzed at the SNP level, then genome-wide association signals can be captured, but the high gene density and linkage disequilibrium make it difficult to determine which variants are causal
Solution Approach 1:
The patent introduces functional intermediaries between genetic variants and asthma phenotype. By evaluating the functional impact of variants on HLA molecule structure and peptide binding capability, the study creates a causal chain: variants → structural/functional changes → altered immune response → asthma risk. This intermediary layer resolves the ambiguity created by linkage disequilibrium.
Solution Approach 2:
The patent replaces the mechanical approach of SNP-based statistical association with a functional/biological mechanism-based approach. Instead of relying on correlation statistics that are confounded by linkage disequilibrium, the study uses functional evaluation of HLA molecules to directly assess causal relationships, substituting statistical mechanics with biological mechanism analysis.
3Reliability
If HLA-DQA2 and HLA-DQB2 expression is inhibited, then asthma treatment can be achieved by targeting specific immune pathways, but the complexity of modulating HLA expression requires precise control mechanisms
Solution Approach 1:
The patent applies local quality by targeting specific HLA molecules (DQA2 and DQB2) rather than suppressing all HLA expression uniformly. This selective modulation allows asthma treatment through targeted immune pathway inhibition while minimizing the complexity of controlling HLA expression across the entire genome. The approach focuses intervention on specific loci with known disease relevance.
Data Source
AI summary
Provided herein are compositions and methods for the characterization and treatment of asthma.